Stock Comparison

JNJ vs PPBT

Johnson & Johnson vs Purple Biotech Ltd

The Verdict

PPBT takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

PPBT

Purple Biotech Ltd

6.6

out of 10

Solid Pick

Head-to-Head

N/A

Market Cap

$6M

N/A

P/E Ratio

0.0

N/A

Profit Margin

0.0%

N/A

Return on Equity

-12.4%

N/A

Debt-to-Equity

0.0

Conservative

Overall Risk

Aggressive

1.0

DVR Score

6.6

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

PPBT6.6/10

Purple Biotech targets high-unmet-need oncology markets with a promising diversified pipeline, including the novel CAPTN-3 tri-specific antibody platform progressing towards IND (Q4 2026) and two Phase 2 assets (CM24, NT219) positioned for partnerships, indicating substantial TAM and significant 10x potential upon clinical success. A crucial positive development since the last analysis is the exte...

Full PPBT Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.